Cervical cancer vaccine proves effective: Test results

October 10, 2005

Final-stage clinical trials of a cervical cancer vaccine developed by University of Queensland (UQ) scientists, have shown the drug to be 100 per cent effective.

The results of the Phase III trials were announced overnight in New York by international pharmaceutical company Merck & Co. who are developing the product.

It was the pioneering research work of Professor Ian Frazer from UQ's Centre for Immunology and Cancer Research (CICR) that led to the development of the vaccine.

Professor Frazer said he was delighted by the news and pleased to have been involved in the vaccine's creation.

"It is very rare, almost unheard of, to achieve a 100% efficacy rate in any treatment, so these results are truly wonderful," he said.

"It is the first time in the world that a vaccine designed to prevent cancer has been developed, and it has happened right here in Australia.

"It is very encouraging to see such great results coming out of Australian research, and developed in conjunction with Australian company CSL, and international pharmaceutical company Merck & Co.

"It is sad that Dr Jian Zhou, who was my research partner, passed away before the work was publicly recognised."

The vaccine is called GardasilTM and it is expected to be submitted for approval by the United States Food and Drug Administration (FDA) within the next two months.

If the drug is approved by the FDA as anticipated by the international scientific community, the vaccine should be commercially available in early 2006.

The trial is part of the ongoing phase III program for GardasilTM, which has involved more than 25,000 people in 33 countries worldwide in total.

Women aged 16 years to 26 years were chosen at random to receive a three-dose regimen of either GardasilTM or placebo at Day 1, Month 2, and Month 6.

GardasilTM was successful in preventing 100 per cent of cases of high-grade pre-cancer and non-invasive cancer associated with human papillomavirus (HPV) strains Type 16 and 18, which cause cervical cancer.

These clinical trial results mirror the outcomes of earlier stage tests also carried out by Merck & Co.

None of the women involved in the trial were forced to pull out as a result of adverse side-affects. The most serious adverse side-affect reported was local discomfort at the injection site.

Cervical cancer is one of the few human cancers that is known to be directly caused by a viral infection.

HPV strain types 16 and 18 lead to the development of cervical cancer, a disease that is the second leading cause of cancer amongst women.

More than 500,000 cases are diagnosed annually and it kills an estimated 275,000 women around the world every year.

Other types of the HPV virus cause genital and skin warts. The HPV's that convey a high risk of cervical cancer are contracted by up to an estimated 70 per cent of sexually active women.

Professor Frazer said GardasilTM would only protect women who were not infected with HPV, but he hoped to change this in the future. "My major focus these days, as indeed it was right back in the beginning, is on developing a vaccine to treat these existing infections," he said.

"We have produced a second vaccine which we hope will do this, however clinical trials are still at a very early stage.

"A therapeutic vaccine to treat already infected individuals is much harder to develop than a vaccine to prevent infection." Professor Frazer hails from Scotland and trained as a renal physician and clinical immunologist in Edinburgh before immigrating to Australia in 1980.

In addition to his responsibilities as Head of CICR, he is the director of a biotechnology start up company, Coridon, which has an interest in optimising and targeting polynucle vaccine protein expression.
-end-
For more information/media interviews: Anton Sanker, Business Manager at CICR, Phone: 61 732 405 938

Research Australia

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.